2 results
Approved WMOCompleted
Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…
Approved WMORecruiting
The primary objective is to determine the efficacy of MagnetOs BCP granules in inducing adequate bone quantity and quality to support endosseous dental implants in the two-staged maxillary sinus floor augmentation procedure. Herein the treatment…